Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aerie begins Phase IIb trial of glaucoma drug PG324
Around 300 patients with glaucoma or ocular hypertension will be enrolled in the 28-day trial, who will compare two concentrations of PG324 to latanoprost and to AR-13324, all
Around 300 patients with glaucoma or ocular hypertension will be enrolled in the 28-day trial, who will compare two concentrations of PG324 to latanoprost and to AR-13324, all
The FDA has issued an action date of 15 September 2014 under the Prescription Drug User Fee Act (PDUFA). Budesonide is a high potency corticosteroid developed to reduce
The trial was carried out under a US Food and Drug Administration (FDA) IND (Investigational New Drug) protocol, and it met all primary and secondary endpoints. A total
The agreement is for both Gelclair, an FDA-approved bioadherent oral rinse gel for treating the painful symptoms of oral mucositis (OM), and Soltamox (tamoxifen citrate) oral liquid solution,
The Phase II clinical trial of ‘tivozanib’ is intended for patients with locally recurrent or metastatic triple negative breast cancer (TNBC). AVEO, which was developing tivozanib in collaboration
Pursuant to the terms of the agreement, YODA will serve as an independent body to review requests from investigators and physicians seeking access to anonymized clinical trials data
BAX 826 is a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness. The amended license
Additionally, Mayo’s Human Cell Therapy Laboratory will manufacture the NurOwn cells for their clinical trial participants. The company said that the other two sites scheduled for the multi-center
The new contract is expected to increase both production and reduce production costs targeting increased sales volume and market share. Imatinib’s market in Russia for 2012 amounted to
Used by Genzyme for its internal product development and external sublicensing, the technology allows a gene therapy Adeno-Associated Viral vector (AAV) to package and deliver more potent therapeutic